Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial

@article{Bissonnette2012EfficacyAS,
  title={Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial},
  author={Robert Bissonnette and Yves Poulin and Y. Zhou and J. Tan and H Chih-Ho Hong and John Webster and Wy Ip and Liping Tang and M Lyle},
  journal={British Journal of Dermatology},
  year={2012},
  volume={166}
}
Background  There is a need for the development of novel nonsteroidal topical drugs for the treatment of atopic dermatitis (AD). 
View on Wiley
ncbi.nlm.nih.gov
61 Citations
Highly Influential Citations
2
Background Citations
16
Methods Citations
1

61 Citations

Citation Type

Citation Type

New and emerging therapies for paediatric atopic dermatitis.
Randomized, double‐blind, placebo‐controlled, multiple‐dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis
TLDR
The goals of this study were to evaluate the safety, tolerability and pharmacokinetics of benvitimod after topical administration in healthy subjects.
A phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis
Topical agents for the treatment of atopic dermatitis
TLDR
A comprehensive overview of new and upcoming topical therapies currently in development and undergoing clinical trials, as well as their safety and efficacy profiles, are provided, and current topicals used in the management of AD are discussed.
Future treatment options for atopic dermatitis - small molecules and beyond.
Phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis
The Future of Atopic Dermatitis Treatment.
  • N. Patel, L. Strowd
  • Biology, Chemistry
    Advances in experimental medicine and biology
  • 2017
TLDR
New advances in AD treatment from medications in the initial stages of development to those nearing FDA approval are discussed, with some formulations that are novel therapies that act as topical biologic or small molecule agents with mechanisms of action similar to systemic treatments.
TREATMENT CHALLENGES IN ATOPIC DERMATITIS WITH NOVEL TOPICAL THERAPIES
TLDR
The majority of emerging therapies for AD are focused on inhibiting phosphodiesterase 4 (PDE4), an enzyme which is increased in inflammatory disorders such as AD.
Therapeutic pipeline for atopic dermatitis: End of the drought?
Emerging Treatment Options in Atopic Dermatitis: Topical Therapies
TLDR
Novel topical therapies are in the pipeline and comprise both new doses and formulations of well-known pharmaceutical molecules and novel approaches targeting unique inflammatory pathways and mechanisms of disease, with a promise of higher efficacy and less harmful side effects.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
A systematic review of the safety of topical therapies for atopic dermatitis
TLDR
The safety of topical therapies for atopic dermatitis, a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how to manage patients.
Treatment of recalcitrant atopic dermatitis with omalizumab.
Severity Scoring of Atopic Dermatitis: The SCORAD Index
TLDR
Assessment methods for atopic dermatitis are not standardized, and therapeutic studies are difficult to interpret, so consensus on these methods is needed to obtain a consensus on them.
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance
TLDR
There is no clinical evidence to establish that treatment with pimecrolimus cream 1% increases the risk of malignancy, and these data demonstrate that topically applied pimeCrolimus is minimally absorbed through the skin and has afavourable safety margin.
Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.
TLDR
In both regressions, appearance subscales of the PARTS explained significant variance beyond that explained by age, sex, skin type, and perceived susceptibility.
Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis
TLDR
Tacrolimus ointment is more effective than pimecrolimus cream in adults with moderate to very severe atopic dermatitis (AD), and both agents have a similar safety profile.
A review of atopic dermatitis
TLDR
Acute eczematous dermatitis manifests vesiculation and bullae and atopic dermatitis involves the eczema process and is known as the itch that rashes.
New insights into atopic dermatitis.
TLDR
This review summarizes recent progress in the understanding of the pathophysiology of atopic dermatitis and the implications for new management strategies.
Future perspectives in the treatment of atopic dermatitis
  • N. Katoh
  • Medicine, Biology
    The Journal of dermatology
  • 2009
TLDR
The limitations of the currently available therapies and the advantages and disadvantages of new approaches for the treatment of atopic dermatitis including topical and systemic immunosuppressants as well as biologics and anti‐pruritic agents are discussed.
...
1
2
...